BioNTech SE (22UA) — Cash Flow Reinvestment Rate
BioNTech SE (22UA) has a Cash Flow Reinvestment Rate of 9.66x as of December 2025, reinvesting €2.99 Billion (capex €62.10 Million plus investments €-2.93 Billion) from operating cash flow of €309.50 Million. Check BioNTech SE cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BioNTech SE Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for BioNTech SE across 5 annual periods. Explore 22UA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for BioNTech SE (2021–2025)
Year-by-year capital reinvestment analysis for BioNTech SE. For live market cap and broader valuation context, see how much is BioNTech SE worth.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 5.83x | €2.66 Billion | €456.00 Million | €749.00 Million | ▼ -41.8% |
| 2024 | 10.03x | €2.08 Billion | €207.70 Million | €452.30 Million | ▲ +713.8% |
| 2023 | 1.23x | €6.62 Billion | €5.37 Billion | €705.50 Million | ▲ +4096.5% |
| 2022 | 0.03x | €398.60 Million | €13.58 Billion | €363.30 Million | ▼ -95.0% |
| 2021 | 0.59x | €522.20 Million | €889.70 Million | €127.50 Million | — |